Home > Healthcare > Pharmaceuticals > Finished Drug Form > Lipid Regulators Market

Lipid Regulators Market Size

  • Report ID: GMI8442
  • Published Date: Mar 2024
  • Report Format: PDF

Lipid Regulators Market Size

Lipid Regulators Market was valued at USD 32.4 billion in 2023 and is set to register a CAGR of 3.8% from 2024 – 2032. The lipid regulators industry is experiencing growth driven by factors such as the rising prevalence of dyslipidemia and cardiovascular disease, advancements in drug development, increased prescription rate, and growing awareness of the importance of lipid management in reducing cardiovascular risk. Also, with the growing ageing population and increasing focus on preventive healthcare, the market is expected witness lucrative growth over the coming years.

 

For instance, according to World Population Prospects 2022, the population aged 65 years and above is expected to rise from 10% in 2022 to 16% in 2050. As the population ages, the risk of developing dyslipidemia and cardiovascular disease also increases, thereby driving the growth of the market.

 

Lipid regulators, also known as lipid-lowering agents or lipid-lowering drugs, are medications used to manage abnormal levels of lipids (fats) in the blood, primarily cholesterol and triglycerides. Elevated levels of these lipids are associated with an increased risk of cardiovascular diseases such as heart attacks and strokes. Lipid regulators can help lower cholesterol and triglyceride levels, reducing the risk of these diseases.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market size for lipid regulators was valued at USD 32.4 billion in 2023 and is set to register 3.8% CAGR from 2024 to 2032, driven by the rising prevalence of dyslipidemia and cardiovascular disease, advancements in drug development, and growing awareness of the importance of lipid management in reducing cardiovascular risk.

The statins segment accounted for 60.1% market share in 2023 and is anticipated to record 4.1% CAGR from 2024 to 2032 as they are recommended as first-line therapy in treatment guidelines issued by organizations such as the American College of Cardiology (ACC).

North America market for lipid regulators accounted for USD 13.6 billion in 2023 and is projected to reach USD 18.1 billion by 2032, as the region faces a significant burden of cardiovascular disease.

AbbVie Inc, Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb, Dr. Reddy's Laboratories Ltd., Merck & Co., Novartis AG, Pfizer, Inc., Sanofi, and Teva Pharmaceuticals.

Lipid Regulators Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 355
  • Countries covered: 19
  • Pages: 203
 Download Free Sample